Qiu Yuting, Zhao Peng, Xu Lin, Zeng Jun, Wu Daobin, Yang Rongying, Fan Xinrong, Liu Bin, Hashimoto Kenji, Chang Lijia, Wei Yan
Key Laboratory of Medical Electrophysiology, Ministry of Education & Medical Electrophysiological Key Laboratory of Sichuan Province, (Collaborative Innovation Center for Prevention of Cardiovascular Diseases), Institute of Cardiovascular Research, Southwest Medical University, Luzhou 646000, Sichuan, China.
Department of Rehabilitation, The Second People's Hospital of Nei Jiang, Neijiang 641000, Sichuan, China.
Phytomedicine. 2025 Jun 16;145:156988. doi: 10.1016/j.phymed.2025.156988.
Cardiovascular diseases (CVDs) are the leading cause of global morbidity and mortality, imposing significant healthcare and economic burdens. Despite advances in treatment, current therapies have limitations that underscore the need for safer and more effective alternatives. Acorus tatarinowii (A. tatarinowii), a well-known herb in traditional Chinese medicine, has shown promising cardioprotective effects, which are primarily attributed to its active compounds, mainly including α-asarone and β-asarone.
This review systematically explores the pharmacological mechanisms by which A. tatarinowii and its bioactive components contribute to CVD management. It also examines the potential of nanotechnology-based delivery systems to enhance their therapeutic efficacy.
We conducted a comprehensive review of recent preclinical and pharmacological studies to evaluate the therapeutic potential, mechanisms of action, and clinical prospects of A. tatarinowii in the treatment of CVDs.
Data were retrieved from Web of Science, PubMed, and ScienceDirect, focusing principally on publications from the past five years. Studies were selected based on their investigation of the pharmacological properties, cardiovascular applications, and nanodelivery formulations of A. tatarinowii and its active compounds.
A. tatarinowii exhibits a range of pharmacological activities, including anti-inflammatory, antioxidant, anti-apoptotic, anti-autophagic, hypolipidemic, and hypoglycemic effects. These mechanisms contribute to its therapeutic potential in managing hypertension, coronary artery disease, heart failure, myocardial ischemia/reperfusion injury, and arrhythmias. Moreover, emerging nano delivery systems, such as lipid nanoparticles and polymeric carriers, have been shown to improve the bioavailability, stability, and overall therapeutic potential of its bioactive compounds while reducing dose-dependent toxicities.
This review highlights A. tatarinowii and its bioactive components as innovative candidates for CVD management. The incorporation of nanotechnology represents a transformative strategy to optimize their pharmacological effects. Future research should focus on clinical validation and further mechanistic studies to facilitate their translation into modern cardiovascular medicine.
心血管疾病（CVDs）是全球发病和死亡的主要原因，带来了巨大的医疗和经济负担。尽管治疗方面取得了进展，但目前的疗法存在局限性，这凸显了对更安全、更有效替代方案的需求。石菖蒲是传统中药中的一种著名草药，已显示出有前景的心脏保护作用，这主要归因于其活性化合物，主要包括α-细辛醚和β-细辛醚。
本综述系统地探讨了石菖蒲及其生物活性成分有助于心血管疾病管理的药理机制。它还研究了基于纳米技术的递送系统提高其治疗效果的潜力。
我们对最近的临床前和药理学研究进行了全面综述，以评估石菖蒲在治疗心血管疾病方面的治疗潜力、作用机制和临床前景。
从科学网、PubMed和ScienceDirect检索数据，主要关注过去五年的出版物。根据对石菖蒲及其活性化合物的药理特性、心血管应用和纳米递送制剂的研究来选择研究。
石菖蒲具有一系列药理活性，包括抗炎、抗氧化、抗凋亡、抗自噬、降血脂和降血糖作用。这些机制有助于其在管理高血压、冠状动脉疾病、心力衰竭、心肌缺血/再灌注损伤和心律失常方面的治疗潜力。此外，新兴的纳米递送系统，如脂质纳米颗粒和聚合物载体，已被证明可以提高其生物活性化合物的生物利用度、稳定性和整体治疗潜力，同时降低剂量依赖性毒性。
本综述强调石菖蒲及其生物活性成分是心血管疾病管理的创新候选物。纳入纳米技术是优化其药理作用的变革性策略。未来的研究应侧重于临床验证和进一步的机制研究，以促进其转化为现代心血管医学。
